Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8496
Epigenetic Strategies to Boost Cancer Immunotherapies
Barrero, Maria Jose CNIO
Int J Mol Sci. 2017;18(6). pii: E1108.
Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic events that take place during immune evasion is critical to providing a rational combined use of immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved in the responses to immunotherapy and how current drugs that target epigenetic regulators impact on them.
The CNIO- Lilly Epigenetics Laboratory is supported by Eli Lilly and Company.
Files in this item
- Epigenetic Strategies to Boost ...